Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin
Abstract The present study aimed to investigate the efficacy and toxicity of pegylated liposomal doxorubicin (PLD) in preoperative neoadjuvant chemotherapy for patients with breast cancer by comparing with conventional anthracycline. This study is a non-randomized controlled trial. Prospective analy...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0142dbe839ec41b5aa9108e70487e916 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0142dbe839ec41b5aa9108e70487e916 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0142dbe839ec41b5aa9108e70487e9162021-12-02T15:08:21ZHigher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin10.1038/s41598-020-80415-w2045-2322https://doaj.org/article/0142dbe839ec41b5aa9108e70487e9162021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80415-whttps://doaj.org/toc/2045-2322Abstract The present study aimed to investigate the efficacy and toxicity of pegylated liposomal doxorubicin (PLD) in preoperative neoadjuvant chemotherapy for patients with breast cancer by comparing with conventional anthracycline. This study is a non-randomized controlled trial. Prospective analysis was conducted after matching as required. A total of 146 patients with confirmed diagnosis of breast cancer by histopathological examinations were enrolled into the observation group and control group in 1:1 ratio. Each of the cases in the observation group was required to correspond to another in the control group according to the requirements including age, molecular subtype, axillary node status, and regimen of the preoperative neoadjuvant chemotherapy. The chemotherapy was based on regimens consisting of anthracyclines, paclitaxel or docetaxel, and/or platinum. PLD was used at least twice in the observation group, with traditional anthracycline as a contrast in the control group. Clinical responses as well as cardiac side effects and other adverse reactions were evaluated by clinical and imaging examinations such as electrocardiogram (ECG) and color Doppler ultrasound during the chemotherapy. Pathologic examinations were performed following the surgeries after preoperative neoadjuvant chemotherapy. All the patients in both groups completed the preoperative neoadjuvant chemotherapy according to their original regimens. The postoperative pathological evaluation revealed a higher pathologic complete response (PCR) rate and significantly more patients of grade V of the Miller-Payne grading system in the observation group as compared to the control group (p = 0.047). In addition, the observation group recorded an evidently lower occurrence of the adverse cardiac events (p = 0.014), ECG changes (p = 0.048), and the relatively severe adverse reactions such as myelosuppression. Compared with conventional anthracycline drugs, PLD has a better pathologic response and safety performance, as well as a similar clinical effectiveness in preoperative neoadjuvant chemotherapy for breast cancer.Weifang LiuWei ChenXiuxiang ZhangPeng ZhaoZhimin FanLirong BiDi WuSijie LiMing YangTong FuDong SongBing HanGang ZhaoYe DuAiping ShiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Weifang Liu Wei Chen Xiuxiang Zhang Peng Zhao Zhimin Fan Lirong Bi Di Wu Sijie Li Ming Yang Tong Fu Dong Song Bing Han Gang Zhao Ye Du Aiping Shi Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin |
| description |
Abstract The present study aimed to investigate the efficacy and toxicity of pegylated liposomal doxorubicin (PLD) in preoperative neoadjuvant chemotherapy for patients with breast cancer by comparing with conventional anthracycline. This study is a non-randomized controlled trial. Prospective analysis was conducted after matching as required. A total of 146 patients with confirmed diagnosis of breast cancer by histopathological examinations were enrolled into the observation group and control group in 1:1 ratio. Each of the cases in the observation group was required to correspond to another in the control group according to the requirements including age, molecular subtype, axillary node status, and regimen of the preoperative neoadjuvant chemotherapy. The chemotherapy was based on regimens consisting of anthracyclines, paclitaxel or docetaxel, and/or platinum. PLD was used at least twice in the observation group, with traditional anthracycline as a contrast in the control group. Clinical responses as well as cardiac side effects and other adverse reactions were evaluated by clinical and imaging examinations such as electrocardiogram (ECG) and color Doppler ultrasound during the chemotherapy. Pathologic examinations were performed following the surgeries after preoperative neoadjuvant chemotherapy. All the patients in both groups completed the preoperative neoadjuvant chemotherapy according to their original regimens. The postoperative pathological evaluation revealed a higher pathologic complete response (PCR) rate and significantly more patients of grade V of the Miller-Payne grading system in the observation group as compared to the control group (p = 0.047). In addition, the observation group recorded an evidently lower occurrence of the adverse cardiac events (p = 0.014), ECG changes (p = 0.048), and the relatively severe adverse reactions such as myelosuppression. Compared with conventional anthracycline drugs, PLD has a better pathologic response and safety performance, as well as a similar clinical effectiveness in preoperative neoadjuvant chemotherapy for breast cancer. |
| format |
article |
| author |
Weifang Liu Wei Chen Xiuxiang Zhang Peng Zhao Zhimin Fan Lirong Bi Di Wu Sijie Li Ming Yang Tong Fu Dong Song Bing Han Gang Zhao Ye Du Aiping Shi |
| author_facet |
Weifang Liu Wei Chen Xiuxiang Zhang Peng Zhao Zhimin Fan Lirong Bi Di Wu Sijie Li Ming Yang Tong Fu Dong Song Bing Han Gang Zhao Ye Du Aiping Shi |
| author_sort |
Weifang Liu |
| title |
Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin |
| title_short |
Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin |
| title_full |
Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin |
| title_fullStr |
Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin |
| title_full_unstemmed |
Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin |
| title_sort |
higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/0142dbe839ec41b5aa9108e70487e916 |
| work_keys_str_mv |
AT weifangliu higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT weichen higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT xiuxiangzhang higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT pengzhao higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT zhiminfan higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT lirongbi higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT diwu higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT sijieli higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT mingyang higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT tongfu higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT dongsong higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT binghan higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT gangzhao higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT yedu higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin AT aipingshi higherefficacyandreducedadversereactionsinneoadjuvantchemotherapyforbreastcancerbyusingpegylatedliposomaldoxorubicincomparedwithpirarubicin |
| _version_ |
1718388166744866816 |